Definium Therapeutics, Inc. (DFTX)

Price$38.09Cached quoteAs of 2026-09-04 16:23 UTC

AI: Overvalued

Price checkThe shares look overvalued because investors already assign billions to an unapproved, pre-revenue drug pipeline.

At roughly $5.17 billion of market value and about $1.1 billion of cash and investments, investors are assigning around $4.1 billion to Definium’s drug pipeline after debt. The company has no product revenue or positive earnings, so normal earnings multiples are unavailable. That valuation can work if DT120 wins approval and meaningful commercial adoption, but it offers little traditional value-investor protection because clinical, regulatory, reimbursement, and launch outcomes remain uncertain.

Big pictureClinical progress is impressive, but losses and research spending are still accelerating rapidly.

Definium generated no operating revenue in the supplied history. Research spending rose from $65.3 million in 2024 to $117.7 million in 2025, while operating cash use increased from $79.1 million to $131.6 million. In the first half of 2026, operating cash use reached $95.4 million and research spending was $90.1 million. The balance sheet now funds operations into 2030 under management’s plan, but cash durability depends on controlling trial and launch spending until a product can generate sales.

Business strengthTwo positive late-stage studies and a large cash reserve reduce financing risk, not development risk.

DT120 produced positive Phase 3 results in major depression and generalized anxiety disorder, with the Voyage study showing a 5.4-point placebo-adjusted anxiety-score improvement at week 12 and meeting all key secondary endpoints. Definium also ended June with about $1.1 billion of cash, equivalents and investments versus roughly $36 million of debt. The tradeoff is dilution: shares outstanding increased from 75.1 million at year-end 2024 to 134.4 million by June 2026, largely after major equity offerings.

What could change the storyAnother strong study and regulatory clarity could support the valuation; setbacks could cut it sharply.

The clearest near-term bull case is another positive generalized-anxiety readout from Panorama, followed by regulatory agreement on a filing path for DT120. The bear case is unusually concentrated because Definium remains pre-revenue and relies heavily on one lead program. Psychedelic-based treatment also requires lengthy supervised dosing sessions, creating commercialization and reimbursement questions even after approval. Traditional economic cyclicality matters less here than binary clinical and regulatory events. A failed pivotal study, filing delay, safety concern, or weak launch economics would materially weaken the pipeline value embedded in the shares.

AI: News

Voyage study succeedsPositive anxiety-study results strengthened DT120’s clinical case and produced a modest same-day stock gain.

On August 12, Definium said the Phase 3 Voyage study met its primary and all key secondary endpoints in generalized anxiety disorder. The 100-microgram dose improved the main anxiety score by 5.4 points versus placebo at week 12, with a large reported effect size and generally favorable tolerability. Shares closed 4.6% higher on unusually heavy volume. The timing is consistent with a positive reaction to the data, although it does not prove the study announcement alone caused the move.

Emerge study succeedsMajor-depression results triggered a sharp revaluation and strengthened confidence in Definium’s lead drug.

On June 22, Definium reported that the Phase 3 Emerge study met its primary and all key secondary endpoints in major depressive disorder, including an 8.1-point placebo-adjusted improvement on the main depression scale at week six. Shares closed nearly 50% higher that day on very heavy volume. The timing strongly suggests investors reacted positively to the clinical data, although broader market factors and expectations around subsequent financing may also have influenced trading.

Large equity raiseThe June share offering transformed the balance sheet but sharply increased the ownership base.

After the Emerge readout, Definium priced 20.6 million new shares at $34 and the underwriters bought another 3.1 million, producing about $805 million of gross proceeds. The financing helped lift cash and investments to roughly $1.1 billion and management says current resources can fund operations into 2030. However, the new shares represent major dilution. The stock fell 1.3% on the first session after the proposed offering, then rose during pricing and closing, so the market reaction was not clearly negative.

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2020

2021

2022

2023

2024

2025

Free cash flow

No reported data

Total cash / debt

CashTotal debt

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020
Revenue	$0	$0	$0	$0	—	—
Research & development	$117.7M	$65.3M	$52.1M	$36.2M	$34.8M	$18.6M
Operating expenses	$166.3M	$103.9M	$93.9M	$66.3M	$93.9M	$33.0M
Operating income	−$166.3M	−$103.9M	−$93.9M	−$66.3M	−$93.9M	−$33.0M
EBITDA	−$178.3M	−$105.9M	−$91.7M	−$63.2M	—	—
Net income	−$183.8M	−$108.7M	−$95.7M	−$56.8M	−$93.0M	−$33.9M
Basic EPSper basic share	-$2.06	-$1.54	-$2.44	-$1.84	-$3.40	-$1.95
Diluted EPSper diluted share	-$2.06	-$1.54	-$2.44	-$1.84	-$3.40	-$1.95

Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

8.36%of listed shares

BlackRock, Inc.11.23M shares · Jun 30, 2026

View holders

Top 20 reported holders of DFTX
Holder	% owned
BlackRock, Inc.	8.36%11.23M shares
Avoro Capital Advisors LLC	5.35%7.19M shares
Driehaus Capital Management LLC	5.09%6.85M shares
Jupiter Topco LLC	4.18%5.62M shares
Capital World Investors	3.99%5.37M shares
FMR LLC	3.54%4.75M shares
PRICE T ROWE ASSOCIATES INC /MD/	3.46%4.65M shares
GEODE CAPITAL MANAGEMENT, LLC	2.71%3.64M shares
STATE STREET CORP	2.28%3.07M shares
Capital International Investors	2.21%2.96M shares
Octagon Capital Advisors LP	2.20%2.95M shares
WELLINGTON MANAGEMENT GROUP LLP	2.20%2.95M shares
Deep Track Capital, LP	2.05%2.75M shares
Commodore Capital LP	1.49%2M shares
ALLIANCEBERNSTEIN L.P.	1.34%1.8M shares
GOLDMAN SACHS GROUP INC	1.34%1.8M shares
CITADEL ADVISORS LLC	1.26%1.69M shares
VANGUARD PORTFOLIO MANAGEMENT LLC	1.23%1.65M shares
RA CAPITAL MANAGEMENT, L.P.	1.12%1.5M shares
VANGUARD CAPITAL MANAGEMENT LLC	1.11%1.49M shares

Percentages use 134.37M shares of this listed class outstanding on Jun 30, 2026.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys4$45.1K disclosed value

Sells (SEC code S)29$5.42M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 25, 2026Form 4 · 10b5-1	Sullivan MarkChief Legal Officer	SellCommon Shares	13.0K	$45.03	$585.8K	320.6K
Jun 25, 2026Form 4 · 10b5-1	Karlin DanielChief Medical Officer	SellCommon Shares	10.0K	$45.03	$451.9K	503.3K
Jun 25, 2026Form 4 · 10b5-1	Roberts BrandiChief Financial Officer	SellCommon Shares	3.0K	$45.03	$135.7K	209.5K
Jun 25, 2026Form 4 · 10b5-1	Barrow RobertChief Executive Officer	SellCommon Shares	29.2K	$45.03	$1.32M	1.10M
Jun 25, 2026Form 4 · 10b5-1	Wiley Matthew T.Chief Commercial Officer	SellCommon Shares	2.9K	$45.03	$129.1K	174.6K